ALung Technologies has presented data from Hemolung respiratory assist system's (RAS) clinical trial.

The trial enrolled seven patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) who were failing non-invasive ventilation and at a high risk of being intubated and placed on invasive mechanical ventilation.

The objective of the study was to assess the potential of the Hemolung RAS to help reduce the need for invasive mechanical ventilation in patients with acute exacerbation of COPD.

Patients in the study were provided Extracorporeal CO2 Removal with the Hemolung RAS to remove retained carbon dioxide.

The trial demonstrated that arterial pCO2 levels were reduced on average by 28% within 24 hours, leading to lessening dyspnea and improved clinical status.

All patients in the study were able to avoid intubation while treating with the Hemolung RAS.

ALung chairman and CEO Peter DeComo said the company is pleased to have completed pilot study of the Hemolung RAS and to be progressing towards obtainment of the CE mark.

"There is tremendous clinical enthusiasm for the Hemolung RAS, and we’re looking forward to introducing the product to key reference centers throughout Europe in the near future," DeComo added.